Picture of Biovaxys Technology logo

BIOV Biovaxys Technology Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m-9.83%
3m+8.68%
6m+166.85%
1yr+115.39%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-30%
50d MA-10.14%
200d MA+56.25%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equity-451.08%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Oct 202331st Oct 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Biovaxys Technology EPS forecast chart

Profile Summary

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

Directors

Last Annual
October 31st, 2022
Last Interim
July 31st, 2023
Incorporated
April 25th, 2018
Public Since
November 21st, 2018
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconCanadian Securities Exchange
Shares in Issue
220,241,658
Blurred out image of a map
Address
146 Thirtieth Street, Suite 100, TORONTO, M8W 3C4
Web
https://biovaxys.com/
Phone
+1 6042628835
Auditors
Dale Matheson Carr-Hilton LaBonte LLP

BIOV Share Price Performance

Upcoming Events for BIOV

Similar to BIOV

Picture of Albert Labs International logo

Albert Labs International

ca flag iconCanadian Securities Exchange

Picture of Algernon Pharmaceuticals logo

Algernon Pharmaceuticals

ca flag iconCanadian Securities Exchange

Picture of Alpha Cognition logo

Alpha Cognition

ca flag iconCanadian Securities Exchange

Picture of Asep Medical Holdings logo

Asep Medical Holdings

ca flag iconCanadian Securities Exchange

Picture of Awakn Life Sciences logo

Awakn Life Sciences

ca flag iconCanadian Securities Exchange

FAQ